Moody’s downgrades Senegal to Caa1 amid rising debt concerns
On September 22, 2025, Nicholas A. Saccomano, President and CEO of OnKure Therapeutics, Inc. (NASDAQ:OKUR), sold 88 shares of Class A Common Stock. The micro-cap biotech company, currently valued at $35.18 million, has seen its stock decline 86% over the past year, though InvestingPro analysis indicates the stock is currently undervalued. The sales were executed at prices ranging from $2.60 to $2.645, resulting in a total transaction value of $230.
The shares were automatically sold to cover tax withholding obligations related to the vesting of restricted stock units. Following the transaction, Saccomano directly owns 3,506 shares, some of which are in the form of restricted stock units, each representing a contingent right to receive one share of Class A Common Stock, subject to vesting. For deeper insights into OKUR’s valuation and 11 additional key investment tips, check out InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.